A Phase IIa Study With Escalating Dose of MS1819-SD

Status Completed

Clinical Trial Summary

This is a Phase IIa study sponsored by AzurRx SAS and Syneos Health is a local representative sponsor and involves testing of a new medication for the compensation of exocrine pancreatic insufficiency (EPI) caused by chronic pacreatitis (CP) and/or distal pancreatectomy. The new medication is called MS1819 Spray Dried (MS1819-SD) which is a lipase produced by the LIP2 gene of Yarrowia lipolytica using recombinant DNA technology.

The primary purpose of this study is to investigate the safety of escalating doses of study drug MS1819-SD in people with chronic pancreatitis. This enzyme has demonstrated an appropriate profile to compensate the pancreatic lipase (enzyme) deficiency that is common with CP patients. The deficiency in this enzyme can be responsible of greasy diarrhea, fecal urge and weight loss.

The design of the study is open-label, meaning that all eligible participants will receive the study drug MS1819-SD. The MS1819-SD dose will increase throughout the study during dose escalation visits in each treatment period; study includes a total of four treatment periods.

The total duration of the MS1819-SD treatment phase is of 48-60 days, The total duration of patient participation in the study is of 74-93 days.

Approximately twelve patients will be enrolled in this study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03481803
Study type	Interventional
Source	AzurRx SAS
Contact
Status	Completed
Phase	Phase 2
Start date	January 27, 2017
Completion date	June 29, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03112759` - Assessing the Utility of Cognitive Behavioral Therapy for Pain Control in Patients With Chronic Pancreatitis	N/A
Enrolling by invitation	`NCT05410795` - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Active, not recruiting	`NCT02965898` - The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis	N/A
Completed	`NCT01452217` - Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers	Phase 1
Completed	`NCT02868047` - Establishing Standards for Normal Pancreatic EUS	N/A
Completed	`NCT00685087` - A Prospective Study of Natural History of Pancreatitis	N/A
Completed	`NCT04949828` - Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
Recruiting	`NCT06068426` - Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management	N/A
Recruiting	`NCT05042284` - Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis	N/A
Active, not recruiting	`NCT05764629` - An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus
Completed	`NCT03850977` - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Recruiting	`NCT05692596` - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Recruiting	`NCT06015945` - Role of Home-based Transcutaneous Electrical Acustimulation for Treatment of Pain in Patients With Chronic Pancreatitis	N/A
Completed	`NCT04619511` - Risk Factors for Post-ESWL and Post-ERCP Pancreatitis
Completed	`NCT03283566` - Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT	Phase 2
Recruiting	`NCT03434392` - QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing	N/A
Not yet recruiting	`NCT05540197` - Arginine-stimulated Prediction of Early Outcome After Islet Transplantation
Completed	`NCT01430234` - Enzyme Suppletion in Exocrine Pancreatic Dysfunction	Phase 4
Completed	`NCT01318369` - Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain	Phase 2
Terminated	`NCT01442454` - Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis	N/A